German enterprise BioNTech and American company Pfizer have jointly developed an experimental vaccine against coronavirus. There's a chance it could reach the world's markets by the end of the year. Ugur Şahin, the BioNTech CEO said so in an interview with CNN.
“We see vaccine responses, we see strong vaccine responses at even low doses. And we believe that this vaccine response since we have seen that in different animal models will also translate into vaccine responses in human subjects," the official said.
The vaccine is already being tested on people in the U.S. and Germany.
According to Şahin, if the vaccine is approved by the governing authorities, partner companies will be ready to speed up its production and entrance to markets so that it becomes available for the population.
"Şahin believes Covid-19 will be responsive to a vaccine which is he calls the “most important aspect” of vaccine development. He said the second aspect is the “very encouraging” pre-clinical data," CNN wrote.